Abstract
Neurodegenerative diseases termed Tauopathies, including Alzheimer disease, are characterized by the presence of intraneuronal neurofibrillary tangles (NFTs), composed by hyperphosphorylated protein Tau. Peptidyl-prolyl cis/trans isomerase Pin1 plays a pivotal role in the regulation of Tau phosphorylation/dephosphorylation state. Indeed, Pin1 specifically recognizes pThr231-Pro232 motif of Tau, catalyzes its isomerisation and, in dependence of the cellular environment, promotes its dephosphorylation by PP2A phosphatase: in the dephosphorylated state Tau is able to exert its physiological activity, promoting microtubules polymerization. However, Pin1 activity in Tauopathies in which Tau is mutated can be harmful, because the isomerase can accelerate progression of the disease. Taking into account the complexity of pathways in which Pin1, under a strict regulation, exerts its biological functions, this isomerase can be consider a promising target in the improvement and design of new therapies against Tauopathies.
Keywords: <, Tau protein, conformation, Pin1 enzyme, role in Alzheimer's disease, pathogenic onset of AD, TauSer262, neurodegeneration, pSer/Thr-Pro, peptidyl-prolyl, Pin1, mediated-transcriptional regulation, Thr668-Pro, MARK
Current Alzheimer Research
Title: Pin1: A New Outlook in Alzheimers Disease
Volume: 8 Issue: 6
Author(s): E. Lonati, M. Masserini and A. Bulbarelli
Affiliation:
Keywords: <, Tau protein, conformation, Pin1 enzyme, role in Alzheimer's disease, pathogenic onset of AD, TauSer262, neurodegeneration, pSer/Thr-Pro, peptidyl-prolyl, Pin1, mediated-transcriptional regulation, Thr668-Pro, MARK
Abstract: Neurodegenerative diseases termed Tauopathies, including Alzheimer disease, are characterized by the presence of intraneuronal neurofibrillary tangles (NFTs), composed by hyperphosphorylated protein Tau. Peptidyl-prolyl cis/trans isomerase Pin1 plays a pivotal role in the regulation of Tau phosphorylation/dephosphorylation state. Indeed, Pin1 specifically recognizes pThr231-Pro232 motif of Tau, catalyzes its isomerisation and, in dependence of the cellular environment, promotes its dephosphorylation by PP2A phosphatase: in the dephosphorylated state Tau is able to exert its physiological activity, promoting microtubules polymerization. However, Pin1 activity in Tauopathies in which Tau is mutated can be harmful, because the isomerase can accelerate progression of the disease. Taking into account the complexity of pathways in which Pin1, under a strict regulation, exerts its biological functions, this isomerase can be consider a promising target in the improvement and design of new therapies against Tauopathies.
Export Options
About this article
Cite this article as:
Lonati E., Masserini M. and Bulbarelli A., Pin1: A New Outlook in Alzheimers Disease, Current Alzheimer Research 2011; 8 (6) . https://dx.doi.org/10.2174/156720511796717140
DOI https://dx.doi.org/10.2174/156720511796717140 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Paris polyphylla: Chemical and Biological Prospectives
Anti-Cancer Agents in Medicinal Chemistry Promising Anti-Fibrotic Approaches for Future Treatment of Systemic Sclerosis
Current Rheumatology Reviews Azoles as Effective Antifungal Agents: Trends, Scope and Relevance
The Natural Products Journal Multi-Targeted Histone Deacetylase Inhibitors in Cancer Therapy
Current Medicinal Chemistry What Does Systems Biology Mean for Drug Development?
Current Medicinal Chemistry Anti-Tumor Activity of Non-Nucleosidic Reverse Transcriptase Inhibitors
Current Pharmaceutical Design The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Genome-wide Analysis of Myelodysplastic Syndromes
Current Pharmaceutical Design RNA Binding Protein/RNA Element Interactions and the Control of Translation
Current Protein & Peptide Science The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Pharmacogenomics of Non-Small Cell Lung Cancer
Current Pharmacogenomics Microarrays as a Tool for Gene Expression Profiling: Application in Ocular and Craniofacial Research
Current Pharmaceutical Analysis An Overview on Small Molecule Inhibitors of BRD4
Mini-Reviews in Medicinal Chemistry Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia
Current Pharmaceutical Design Drug-Induced Hypokalaemia
Current Drug Safety Chemistry and Biological Activity of [1,2,3]-Benzotriazine Derivatives
Current Organic Chemistry